AGAlexandra Griffith

Alexandra Griffith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Griffith has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Programming angiogenesis with tunable assemblies of multifunctional peptides

    by Joseph Dodd-O, Bobak Shadpoor, Abhishek Roy, Roya Jafari, Tarunya R. Sudarshan, Abigail Holberton, Dongjing He, Francesco Coppola, Daniel M. Dinakarapandian, Deep Malu, et al.

    Therapeutic angiogenesis is constrained by the inability to localize, sustain, and finely tune vascular signaling. Here, we detail a supramolecular peptide system that enables angiogenic programming by decoupling mechanical integrity from receptor-level bioactivity. We integrate a vascular endothelial growth factor (VEGF)–mimetic amphiphile (SLan) with a mechanically robust β sheet peptide (K1) to yield injectable nanofiber hydrogels with tunable stiffness (100 to 1000 pascals) and preserved vascular endothelial growth factor receptor 2 (VEGFR2) affinity. Molecular dynamics simulations and solid-state nuclear magnetic resonance revealed that the coassembly mitigates steric interference between domains, enabling dense supramolecular packing while maintaining optimal receptor accessibility. The resulting SLan-K1 formulation preserves the secondary structure, activating canonical VEGFR2–MEK (mitogen-activated protein kinase kinase)–ERK (extracellular signal–regulated kinase). In vitro, these hydrogels induce endothelial proliferation; in vivo, they drive rapid neovascular infiltration and stable vascular integration in murine and rodent implants. This design unites peptide self-assembly, receptor binding kinetics, and immunophenotypic outcomes in defining a molecular framework for tunable angiogenic materials. This strategy establishes a modular platform for engineering instructive microenvironments that bridge molecular design and tissue-scale functionality.


  • Self-Assembling Peptides with Insulin-Like Growth Factor Mimicry

    by Abhishek Roy, Joseph B. Dodd-O, Alicia S. Robang, Dongjing He, Owen West, Zain Siddiqui, Erika Davidoff Aguas, Hannah Goldberg, Alexandra Griffith, Corey Heffernan, et al.

    Growth factor (GF) mimicry involves recapitulating the signaling of larger molecules or cells. Although GF mimicry holds considerable promise in tissue engineering and drug design applications, difficulties in targeting the signaling molecule to the site of delivery and dissociation of mimicking peptides from their target receptors continue to limit its clinical application. To address these challenges, we utilized a self-assembling peptide (SAP) platform to generate synthetic insulin-like growth factor (IGF)-signaling, self-assembling GFs. Our peptide hydrogels are biocompatible and bind target IGF receptors in a dose-dependent fashion, activate proangiogenic signaling, and facilitate formation of angiogenic microtubules in vitro. Furthermore, infiltrated hydrogels are stable for weeks to months. We conclude that the enhanced targeting and long-term stability of our SAP/GF mimicry implants may improve the efficacy and safety of future GF mimic therapeutics.


  • Open Access

    Proof of concept design for a toothbrush with on‐board vacuum to reduce oral aspirates

    by Alexandra Griffith, Abhishek Roy, Sahitya Kulkarni, Glennon Simmons, Laura Osorno, Vivek Kumar

    Background: Over the course of brushing, aerosolised particles develop in the mouth. In individuals who do not have the ability to expel these oral aspirates, they can be inhaled and cause aspiration pneumonia. This article showcases a novel vacuum toothbrush, termed “ToothVac,” and provides findings from its first human trial.Methods: The ToothVac device suctions saliva and aspirates during brushing, storing them in a removable reservoir at the bottom of the brush, to minimise the risk of inhalation and subsequent infection. Further descriptions of the various components of the ToothVac are included. This trial involved 18 participants who brushed using the ToothVac with the vacuum suction turned on and then off.Results: The volume of saliva produced was measured and compared. The ToothVac significantly reduced the amount of saliva that was produced by these participants when brushing.Conclusion: The device has potential clinical potential in that it may reduce the risk of aspiration pneumonia and related lung infections. Potential future research may include clinical trials for specific indications or marketing for oral aspirate removal, as well as optimisation of brush design using injection moulding for scalable manufacturing.